How Can We Engineer CAR T Cells to Overcome Resistance?

Código QR

How Can We Engineer CAR T Cells to Overcome Resistance?

Maya Glover,1 Stephanie Avraamides,2 John Maher1– 4 1Leucid Bio Ltd., Guy’s Hospital, London, SE1 9RT, UK; 2King’s College London, School of Cancer and Pharmaceutical Sciences, Guy’s Hospital, London, SE1 9RT, UK; 3Department of Clinical Immunology and Allergy...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Glover M, Avraamides S, Maher J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	chimeric antigen receptor cancer immunotherapy t-cell resistance Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/83cff87a5797459291983d07914ea971
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
por: Camilla M. Grunewald, et al.
Publicado: (2021)

Spinoculation and retronectin highly enhance the gene transduction efficiency of Mucin-1-specific chimeric antigen receptor (CAR) in human primary T cells
por: Alireza Rajabzadeh, et al.
Publicado: (2021)

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
por: Christopher Sloas, et al.
Publicado: (2021)

Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
por: Cristina Aparicio, et al.
Publicado: (2021)

Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application
por: Yu-Ge Zhu, et al.
Publicado: (2021)

The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy
por: Hamilton G, et al.
Publicado: (2021)

Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
por: Mehran Bahraini, et al.
Publicado: (2021)

CAR-T and other adoptive cell therapies for B cell malignancies
por: Peihua Lu, et al.
Publicado: (2021)

Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience
por: Schaefer A, et al.
Publicado: (2021)

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation
por: Virginia Picanço-Castro, et al.
Publicado: (2021)

CELLULAR IMMUNOTHERAPY: A MODERN APPROACH TO TREATMENT OF ONCOLOGICAL DISEASES
por: Yu. N. Lezhnin, et al.
Publicado: (2018)

Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy
por: Yan-Ruide Li, et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study
por: Kiwan Kim, et al.
Publicado: (2021)

Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies
por: Jessica Waibl Polania, et al.
Publicado: (2021)

Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission
por: Yiyun Wang, et al.
Publicado: (2021)

SHORT OVERVIEW OF CLINICAL TRIALS WITH CURRENT IMMUNOTHERAPEUTIC TOOLS FOR CANCER TREATMENT
por: T. S. Nepomnyashchikh, et al.
Publicado: (2017)

CAR T Cell Therapy’s Potential for Pediatric Brain Tumors
por: Pauline Thomas, et al.
Publicado: (2021)

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles’ Heel?
por: Leonardo M. R. Ferreira, et al.
Publicado: (2021)

Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?
por: Léonce Kouakanou, et al.
Publicado: (2021)

A novel CD34-derived hinge for rapid and efficient detection and enrichment of CAR T cells
por: Arthur Bister, et al.
Publicado: (2021)

Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences
por: Tor Henrik Anderson Tvedt, et al.
Publicado: (2021)

Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma
por: Tiantian Ma, et al.
Publicado: (2021)

c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer
por: Chung Hyo Kang, et al.
Publicado: (2021)

Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway
por: Chunyi Shen, et al.
Publicado: (2021)

Quantification of cell-free DNAfor the analysis of CD19-CAR-T cells during lymphoma treatment
por: Thomas Mika, et al.
Publicado: (2021)

Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020
por: Jianhua Du, et al.
Publicado: (2021)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Sergey Kulemzin, et al.
Publicado: (2021)

New insights to the functional role of the T cell-Antigen Presenting Cell immunological synapse
por: FAROUDI,MUSTAPHA, et al.
Publicado: (2002)

Self-Assembled Nanoparticles Prepared from Low-Molecular-Weight PEI and Low-Generation PAMAM for EGFRvIII-Chimeric Antigen Receptor Gene Loading and T-Cell Transient Modification
por: Yu Q, et al.
Publicado: (2020)

Monoclonal Antibody Therapies for High Risk Neuroblastoma
por: Furman WL
Publicado: (2021)

Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells
por: Shin Yi Tang, et al.
Publicado: (2021)

The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
por: Elena V. Abakushina, et al.
Publicado: (2021)

Implementing Logic Gates for Safer Immunotherapy of Cancer
por: Mohammed Azharuddin Savanur, et al.
Publicado: (2021)

PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses
por: Song S, et al.
Publicado: (2019)

Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review
por: Bayarmagnai Weinstein, et al.
Publicado: (2021)

Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells
por: Motahareh Arjomandnejad, et al.
Publicado: (2021)

Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCs
por: Francian A, et al.
Publicado: (2017)

INDUCTION OF T-CELL IMMUNE RESPONSE IN CHRONIC HCV-INFECTED PATIENTS WITH UNDERLYING DENDRITIC CELL IMMUNOTHERAPY
por: E. R. Chernykh, et al.
Publicado: (2017)

Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy
por: Dong Y, et al.
Publicado: (2020)

Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody
por: Saeed M, et al.
Publicado: (2016)